Evidence map›Paper›PMID 42106368›Full record

ArticleNPJ vaccines2026

LNP-based delivery of a Toll-like receptor 9 agonist elicits potent adjuvant effects and antitumor immunity.

Yarong Zeng, Jialin Xu, Feng Han, Sibo Zhang, Rong Su, Yufang Li, Renfei Gao, Xiuli Zhang, Lizhi Zhou, Tingting Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yarong Zeng *State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Jialin Xu *State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Feng HanState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Sibo ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Rong SuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Yufang LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Renfei GaoState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Xiuli ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Lizhi ZhouState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Tingting LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Hai YuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Qingbing ZhengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Ningshao XiaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China.
Shaowei LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China. shaowei@xmu.edu.cn.
Ying GuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China. guying@xmu.edu.cn.

Funding

National Natural Science Foundation of China 82302062National Natural Science Foundation of China 82473313the Fundamental Research Funds for the Central Universities 20720220006the National Key Research and Development Program of China 2024YFC2310401the Natural Science Foundation of Xiamen, China 3502Z20227165Xiamen Industry-Academia-Research Projects 2024CXY0113Xiang An Innovation Laboratory Science and Technology Plan Project 2023XAKJ0101019
6 · The paper itself

Abstract

The success of therapeutic cancer vaccines hinges on overcoming the immunosuppressive tumor microenvironment (TME) and activating robust, durable cellular immunity. Here, we engineered a highly translatable vaccine adjuvant delivery system (LNPC) by integrating the Toll-like receptor 9 (TLR9) agonist CpG with the FDA-approved ionizable lipid ALC-0315. This lipid nanoparticle (LNP) architecture establishes a safe, localized immunological depot that completely shields CpG from systemic nuclease degradation. Crucially, it enables the spatiotemporally coordinated co-delivery of physically admixed antigens and features a "smart" pH-responsive mechanism for targeted endosomal payload release. Consequently, LNPC efficiently activates the TLR9/MyD88 signaling pathway, promotes robust dendritic cell maturation, and drives a pronounced Th1-biased polarization. It uniquely induces the massive expansion of polyfunctional CD8

Identifiers

PMID42106368
PMCPMC13377064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.